Dosing designed with patient needs in mind
Actor portrayal.
GOMEKLI is taken on a 3-weeks-on/1-week-off dosing schedule1
- The recommended dose is 2 mg/m2 twice daily, with a maximum dose of 4 mg twice daily1
- GOMEKLI can be taken with or without food1
GOMEKLI is available in 2 dosing formulations1
A tablet that can be dispersed in water or swallowed whole
A capsule that comes in 2 sizes
The tablet for oral suspension (dispersible tablet) may help more patients2
Learn more about how to help patients prepare GOMEKLI for oral suspension
If dosing GOMEKLI as an oral suspension, instruct patients to1:
Gently swirl the water and tablets until the tablets are fully dispersed and an oral suspension is obtained. It takes approximately 2 to 4 minutes to fully disperse the tablets. Once the tablets are dispersed, the oral suspension will appear white and cloudy.
Administer the oral suspension immediately after preparation from a dosing cup or oral syringe.
After administration of the prepared suspension, add approximately 5 mL to 10 mL of drinking water to the dosing cup and gently swirl to resuspend any remaining particles. Administer the suspension to ensure the full dose is taken. Discard the oral suspension if not administered within 30 minutes after preparation.
*An exploratory, cross-sectional, noninterventional study consisting of 2 anonymous surveys directed at adult patients with NF1-PN and caregivers of pediatric patients with NF1-PN.4
Determining a patient’s dose based on body surface area (BSA)1
Recommended dosage for capsules or tablets for oral suspension
0.40 to 0.69
1 mg twice daily
0.70 to 1.04
2 mg twice daily
1.05 to 1.49
3 mg twice daily
≥1.50
4 mg twice daily
It is important to monitor your patients and reassess dosage based on any BSA changes.
Continue treatment with GOMEKLI until disease progression or unacceptable toxicity.
View recommended dose reductions/modifications for GOMEKLI
Recommended dose reductions for adverse reactions1
BSA (m2)
Reduced dose‡
0.40 to 0.69
2 mg
1 mg
2 mg
2 mg
3 mg
3 mg
Recommended dose modifications for adverse reactions1
Severity of adverse reaction§
Recommended dosage modification
Ocular toxicity
Grade ≤2
- Continue GOMEKLI at current dose level
- Consider ophthalmologic examinations every 2 to 4 weeks until resolution to ≤Grade 1 or baseline
Grade ≥3
- Withhold GOMEKLI until ≤Grade 1 or baseline
- If recovery occurs ≤14 days, resume GOMEKLI at the next lower dose
- If recovery occurs in >14 days, consider permanent discontinuation of GOMEKLI
Symptomatic retinal pigment epithelium detachment (RPED)
- Withhold GOMEKLI until ≤Grade 1 or baseline
- Resume GOMEKLI at the same dose
Retinal vein occlusion (RVO)
- Permanently discontinue GOMEKLI
Asymptomatic, absolute decrease in LVEF of 10% or greater from baseline and is less than the lower limit of normal
- Withhold GOMEKLI until ≤Grade 1
- Resume GOMEKLI at reduced dose
- Permanently discontinue GOMEKLI
Intolerable Grade 2 or Grade 3
- Withhold GOMEKLI until ≤Grade 1
- Resume GOMEKLI at reduced dose
Grade 3 or 4 dermatitis acneiform or nonacneiform rash
- Withhold GOMEKLI until ≤Grade 1
- Resume GOMEKLI at reduced dose
Other adverse reactions
Intolerable Grade 2 or Grade 3
- Withhold GOMEKLI until ≤Grade 1
- Resume GOMEKLI at reduced dose
Grade 4
- Consider permanent discontinuation of GOMEKLI
‡Permanently discontinue GOMEKLI in patients unable to tolerate GOMEKLI after one dose reduction.
§Per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v. 5.0).
†The recommended dosage for patients with a BSA less than 0.40 m2 has not been established.1
Routine tests before and during treatment
Pregnancy test
Lab work
Blood tests and urinalysis should be initiated prior to treatment, and at regular intervals during treatment, to assess for abnormalities (ie, changes in serum CPK).2
Ophthalmic assessment
Dosing modifications
The GOMEKLI Dosing and Adverse Reaction Management Guide includes an overview of GOMEKLI dosing and administration as well as guidance on managing adverse reactions that may occur during treatment.
Personalized support
Indication
GOMEKLI (mirdametinib) is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
Important Safety Information
Warnings and Precautions
Ocular Toxicity: GOMEKLI can cause ocular toxicity including retinal vein occlusion (RVO), retinal pigment epithelium detachment (RPED), and blurred vision. In the adult pooled safety population, ocular toxicity occurred in 28% of patients treated with GOMEKLI: 21% were Grade 1, 5% were Grade 2 and 1.3% were Grade 3. RVO occurred in 2.7%, RPED occurred in 1.3%, and blurred vision occurred in 9% of adult patients. In the pediatric pooled safety population, ocular toxicity occurred in 19% of patients: 17% were Grade 1 and 1.7% were Grade 2. Conduct comprehensive ophthalmic assessments prior to initiating GOMEKLI, at regular intervals during treatment, and to evaluate any new or worsening visual changes such as blurred vision. Continue, withhold, reduce the dose, or permanently discontinue GOMEKLI as clinically indicated.
Left Ventricular Dysfunction: GOMEKLI can cause left ventricular dysfunction. GOMEKLI has not been studied in patients with a history of clinically significant cardiac disease or LVEF <55% prior to initiation of treatment. In the ReNeu study, decreased LVEF of 10 to <20% occurred in 16% of adult patients treated with GOMEKLI. Five patients (9%) required dose interruption, one patient (1.7%) required a dose reduction, and one patient required permanent discontinuation of GOMEKLI. The median time to first onset of decreased LVEF in adult patients was 70 days. Decreased LVEF of 10 to <20% occurred in 25%, and decreased LVEF of ≥20% occurred in 1.8% of pediatric patients treated with GOMEKLI. One patient (1.8%) required dose interruption of GOMEKLI. The median time to first onset of decreased LVEF in pediatric patients was 132 days. All patients with decreased LVEF were identified during routine echocardiography, and decreased LVEF resolved in 75% of patients. Before initiating GOMEKLI, assess ejection fraction (EF) by echocardiogram. Monitor EF every 3 months during the first year and then as clinically indicated. Withhold, reduce the dose, or permanently discontinue GOMEKLI based on severity of adverse reaction.
Dermatologic Adverse Reactions: GOMEKLI can cause dermatologic adverse reactions including rash. The most frequent rashes included dermatitis acneiform, rash, eczema, maculo-papular rash and pustular rash. In the pooled adult safety population, rash occurred in 92% of patients treated with GOMEKLI (37% were Grade 2 and 8% were Grade 3) and resulted in permanent discontinuation in 11% of patients. In the pooled pediatric safety population, rash occurred in 72% of patients treated with GOMEKLI (22% were Grade 2 and 3.4% were Grade 3) and resulted in permanent discontinuation in 3.4% of patients. Initiate supportive care at first signs of dermatologic adverse reactions. Withhold, reduce the dose, or permanently discontinue GOMEKLI based on severity of adverse reaction.
Embryo-Fetal Toxicity: GOMEKLI can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the initiation of GOMEKLI. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Also advise patients to use effective contraception during treatment with GOMEKLI and for 6 weeks after the last dose (females) or 3 months after the last dose (males).Adverse Reactions
The most common adverse reactions (>25%) in adult patients were rash (90%), diarrhea (59%), nausea (52%), musculoskeletal pain (41%), vomiting (38%), and fatigue (29%). Serious adverse reactions occurred in 17% of adult patients who received GOMEKLI. The most common Grade 3 or 4 laboratory abnormality (>2%) was increased creatine phosphokinase.
The most common adverse reactions (>25%) in pediatric patients were rash (73%), diarrhea (55%), musculoskeletal pain (41%), abdominal pain (39%), vomiting (39%), headache (34%), paronychia (32%), left ventricular dysfunction (27%), and nausea (27%). Serious adverse reactions occurred in 14% of pediatric patients who received GOMEKLI. The most common Grade 3 or 4 laboratory abnormalities (>2%) were decreased neutrophil count and increased creatine phosphokinase.Use in Specific Populations
Indication
References
- GOMEKLI. Prescribing Information. SpringWorks Therapeutics, Inc.
- Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. Published online November 8, 2024. doi.org/10.1200/JCO.24.01034
- Rapado F, Simo R, Small M. Neurofibromatosis type 1 of the head and neck: dilemmas in management. J Laryngol Otol. 2001;115(2):151-154.
- Yoo HK, Porteous A, Ng A, et al. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey. BMC Neurology. 2023;23(1):419.